|
Investors have put about $7.8 billion into Boston-area startups in 2026, making the region on track for a moderate annual gain and the strongest tally in about four years.
Coralogix, a Boston-headquartered software-monitoring startup, raised $200 million in a Series F round, valuing the company at $1.6 billion. It helps monitor autonomous AI-driven software systems, and has grown revenue by over 60% in the past year.
Beeline Medicines, a new biotech venture, launched with a $300 million Series A funding round led by Bain Capital. The company licensed five autoimmune programs, with its lead program being afimetoran, a daily oral small molecule targeting TLR7 and TLR8.
Blackstone Life Sciences invested $250 million in Anagram Therapeutics to support the development, regulatory approval, and commercial launch of ANG003, an oral recombinant enzyme replacement therapy for exocrine pancreatic insufficiency linked to conditions like cystic fibrosis and pancreatic cancer.
|